Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 8/20 | 0.34 |
| ▸ | DRD2 | P14416 | 7/20 | 0.34 |
| ▸ | DRD3 | P35462 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL659567 | 0.90 | MAPT (0.44) | MAPTDRD4DRD2MEN1KMT2A | |
| SCHEMBL658811 | 0.89 | MAPT (0.36) | MAPTGAARAD52DRD2MEN1 | |
| SCHEMBL660130 | 0.89 | GAA (0.33) | MAPTGAAADRB1RAD52DRD2 | |
| SCHEMBL659855 | 0.87 | PIK3CA (0.36) | MAPTGAARAD52MEN1KMT2A | |
| SCHEMBL661032 | 0.86 | AKR1C3 (0.40) | MAPTGAAADRB1MEN1KMT2A | |
| SCHEMBL657755 | 0.84 | HSP90AA1 (0.32) | MEN1KMT2A | |
| SCHEMBL659624 | 0.84 | LMNA (0.40) | MAPTGAAMEN1KMT2AHTT | |
| SCHEMBL657676 | 0.84 | MEN1 (0.41) | MAPTGAAADRB1DRD4DRD2 | |
| SCHEMBL659593 | 0.83 | HTR7 (0.37) | MAPTGAAMEN1KMT2AHTT | |
| SCHEMBL658656 | 0.82 | LMNA (0.34) | MAPTGAAKMT2AALDH1A1GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957069-B2 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-17 | — | — | US | disclosed |
| US-8957069-B2 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-17 | — | — | US | disclosed |
| US-8957069-B2 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-17 | — | — | US | disclosed |
| EP-2781513-A1 | Benzofuran derivatives | Takeda Pharmaceutical Company Limited (JP) | 2014-09-24 | — | — | EP | disclosed |
| EP-2781513-A1 | Benzofuran derivatives | Takeda Pharmaceutical Company Limited (JP) | 2014-09-24 | — | — | EP | disclosed |
| EP-2406243-B1 | BENZOFURAN DERIVATIVES | TAKEDA PHARMACEUTICAL (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-8288390-B2 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288390-B2 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120232096-A1 | BENZOFURAN DERIVATIVES | TSUKAMOTO TETSUYA (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120232096-A1 | BENZOFURAN DERIVATIVES | TSUKAMOTO TETSUYA (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120232095-A1 | BENZOFURAN DERIVATIVES | TSUKAMOTO TETSUYA (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120232095-A1 | BENZOFURAN DERIVATIVES | TSUKAMOTO TETSUYA (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120232095-A1 | BENZOFURAN DERIVATIVES | TSUKAMOTO TETSUYA (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120046277-A1 | BENZOFURAN DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-23 | — | — | US | disclosed |
| US-20120046277-A1 | BENZOFURAN DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-23 | — | — | US | disclosed |
| EP-2406243-A1 | BENZOFURAN DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2012-01-18 | — | — | EP | disclosed |
| US-20100234357-A1 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| WO-2010104194-A1 | BENZOFURAN DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | WO | disclosed |
| US-20100234357-A1 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232096-A1 | BENZOFURAN DERIVATIVES | AHR, BRPF3, CBR3 | MAPT 3969/4885GAA 4738/4885ADRB1 294/4885 |
| US-20100234357-A1 | Benzofuran derivatives | AHR, BRPF3, CBR3 | MAPT 3969/4885GAA 4738/4885ADRB1 294/4885 |
| US-20120232095-A1 | BENZOFURAN DERIVATIVES | AHR, BRPF3, CBR3 | MAPT 3969/4885GAA 4738/4885ADRB1 294/4885 |
| US-20120046277-A1 | BENZOFURAN DERIVATIVES | BRPF3, BRD1, CBR3 | MAPT 4353/4885GAA 4790/4885ADRB1 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.